Roivant Sciences (ROIV) Stock Price
Roivant Sciences Price
Revenue has compounded at 19.9% per year over the past 7 years to 8.26 M USD. Roivant Sciences's net margin stands at -3,629.2%, down from -1,528.9% several years earlier. Analysts set a median price target of 26.52 USD, implying 35.2% below the current price. Of 18 analysts, 16 rate the stock a buy — an overall Buy consensus. The stock trades about 193% above its 52-week low.
Roivant Sciences stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Roivant Sciences over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Roivant Sciences stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Roivant Sciences's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Roivant Sciences Price |
|---|---|
| 9/10/2026 | 40.94 USD |
| 9/9/2026 | 41.81 USD |
| 9/8/2026 | 41.84 USD |
| 9/4/2026 | 34.47 USD |
| 9/3/2026 | 34.41 USD |
| 9/2/2026 | 34.18 USD |
| 9/1/2026 | 34.52 USD |
| 8/31/2026 | 34.76 USD |
| 8/28/2026 | 35.78 USD |
| 8/27/2026 | 37.04 USD |
| 8/26/2026 | 36.75 USD |
| 8/25/2026 | 36.47 USD |
| 8/24/2026 | 36.26 USD |
| 8/21/2026 | 36.30 USD |
| 8/20/2026 | 36.84 USD |
| 8/19/2026 | 36.80 USD |
| 8/18/2026 | 36.05 USD |
| 8/14/2026 | 36.20 USD |
| 8/13/2026 | 36.28 USD |
| 8/12/2026 | 36.23 USD |
| 8/10/2026 | 35.93 USD |
| 8/7/2026 | 36.34 USD |
| 8/6/2026 | 35.12 USD |
| 8/5/2026 | 34.66 USD |
| 8/4/2026 | 34.35 USD |
| 8/3/2026 | 33.32 USD |
| 7/31/2026 | 33.91 USD |
| 7/30/2026 | 34.52 USD |
| 7/29/2026 | 33.50 USD |
| 7/27/2026 | 35.03 USD |
Roivant Sciences Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Roivant Sciences Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 0.07 | 0.02 | 0.06 | 0.03 | 0.03 | 0.03 | 0.01 | 0.05 | 0.39 | 1.51 | 3.25 | 5.08 |
| – | 3,250.00 | -65.67 | 139.13 | -43.64 | 3.23 | -9.38 | -72.41 | 537.50 | 672.55 | 282.49 | 115.73 | 56.20 |
| 50.00 | 98.51 | 91.30 | 83.64 | 90.32 | 96.88 | 96.55 | 75.00 | 75.00 | 75.00 | 75.00 | 75.00 | 75.00 |
| – | 0.07 | 0.02 | 0.05 | 0.03 | 0.03 | 0.03 | 0.01 | 0.04 | 0.30 | 1.13 | 2.44 | 3.81 |
| -0.75 | -0.53 | -0.90 | -0.92 | -0.81 | -0.82 | -1.11 | -1.29 | -1.06 | -1.07 | -0.41 | 1.22 | 2.37 |
| -37,400.00 | -794.03 | -3,891.30 | -1,667.27 | -2,609.68 | -2,575.00 | -3,837.93 | -16,062.50 | -2,080.39 | -270.81 | -27.07 | 37.50 | 46.59 |
| -1.04 | 1.20 | -0.81 | -0.85 | -1.01 | 4.35 | -0.17 | -0.30 | -0.98 | -0.93 | -0.26 | 1.04 | 2.03 |
| – | -215.27 | -167.42 | 4.45 | 19.41 | -530.92 | -103.93 | 74.85 | 227.76 | -5.41 | -71.74 | -496.95 | 95.00 |
| 720.78 | 684.79 | 686.59 | 713.32 | 844.46 | 722.72 | 696.86 | 720.78 | 720.78 | 720.78 | 720.78 | 720.78 | 720.78 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Roivant Sciences generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Roivant Sciences retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Roivant Sciences's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Roivant Sciences has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Roivant Sciences's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Roivant Sciences stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Roivant Sciences Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Roivant Sciences business model & stock analysis
Roivant Sciences SWOT Analysis
Strengths
1. Strong Research and Development capabilities, enabling development of innovative drugs and therapies.
2. Well-established partnerships with leading pharmaceutical companies, providing access to resources, expertise, and potential collaborations.
3. Diverse portfolio of drug candidates across various therapeutic areas, reducing dependency on a single product.
Weaknesses
1. Relatively small market presence compared to larger pharmaceutical companies, limiting brand recognition and market share.
2. High dependence on external sources for funding research and development activities, making the company vulnerable to changes in funding availability.
3. Limited manufacturing capabilities, potentially impacting the speed and efficiency of drug production.
Opportunities
1. Growing demand for innovative and personalized healthcare solutions, creating opportunities for Roivant Sciences Ltd to capitalize on its R&D expertise.
2. Expansion into emerging markets with favorable regulatory environments, allowing for increased market penetration.
3. Potential collaborations with academic institutions and research organizations to further enhance R&D capabilities.
Threats
1. Intense competition within the pharmaceutical industry, with larger players having significant resources and established market positions.
2. Stringent regulatory requirements and lengthy approval processes, posing challenges and delays in bringing new drugs to market.
3. Uncertainty surrounding healthcare policies and reimbursement systems, potentially impacting the demand and pricing of drugs.
Roivant Sciences Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Roivant Sciences Segments
Roivant Sciences Revenue by Segment
3 Years
Max
Details
Roivant Sciences Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Roivant Sciences historical P/E ratio, EBIT multiple, and P/S ratio
Roivant Sciences annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Roivant Sciences shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Roivant Sciences stock splits
Current Roivant Sciences forecasts and price targets in September 2026
Analyst Price Targets 2026Roivant Sciences Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/10/2026 | Maintained | Buy | 45 | |
| 8/7/2026 | Maintained | Buy | – | |
| 8/7/2026 | Maintained | Buy | 39 | |
| 5/26/2026 | Maintained | Buy | 39 | |
| 5/21/2026 | Maintained | Buy | 58 | |
| 5/21/2026 | Maintained | Buy | – | |
| 5/21/2026 | Maintained | Buy | 45 | |
| 4/16/2026 | Maintained | Overweight | 54 | |
| 3/4/2026 | Maintained | Buy | – | |
| 2/10/2026 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Roivant Sciences Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/11/2024 | -0.26USD | - | 50.20 MUSD | - | 2025 Q2 |
| 6/26/2024 | -0.33USD | - | 35.41 MUSD | - | 2024 Q4 |
| 2/12/2024 | -0.33USD | - | 31.77 MUSD | - | 2024 Q3 |
| 11/14/2022 | -0.44USD | - | 5.74 MUSD | - | 2023 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Roivant Sciences stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Roivant Sciences shareholder structure
| % | Name |
|---|---|
10.75017% | |
7.14484% | |
6.10071% | |
3.46862% | |
3.11823% | |
2.85094% |
Roivant Sciences Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
55.90% | SEC ↗ | |
18.70% | SEC ↗ | |
14.40% | SEC ↗ | |
14.40% | SEC ↗ | |
14.40% | SEC ↗ | |
14.40% | SEC ↗ | |
14.28% | SEC ↗ | |
14.19% | SEC ↗ | |
12.80% | SEC ↗ | |
12.80% | SEC ↗ |
Roivant Sciences Executives and Management Board
12 members · avg. age 48 · 25 % women
Dr. Mayukh Sukhatme (49)
President, Chief Investment Officer, Director · since 2021
251.86 M USD
Management
Mr. Matthew Gline (41)
Chief Executive Officer, Director · since 2017
Dr. Eric Venker (38)
President and Immunovant Chief Executive Officer
Mr. Richard Pulik (46)
Chief Financial Officer
Ms. Jennifer Humes (44)
Chief Accounting Officer
Dr. Frank Torti (46)
President and Vant Chairman
Board of Directors
Mr. Ilan Oren (41)
Independent Chairman of the Board
Ms. Melissa Epperly (48)
Independent Director
Mr. Daniel Gold (57)
Independent Director
Ms. Meghan Fitzgerald (54)
Independent Director
Dr. Keith Manchester (56)
Independent Director
Mr. James Momtazee (53)
Independent Director
Frequently asked questions about Roivant Sciences
Roivant Sciences Ltd has a unique business model focused on creating and developing innovative biopharmaceutical companies. They identify and acquire promising drug candidates from research organizations and pharmaceutical companies, and then allocate resources to further develop and commercialize these potential therapies. By operating a centralized infrastructure, Roivant provides expertise in areas such as clinical development, regulatory affairs, and commercialization, enabling their subsidiary companies to focus on scientific advancements. Their mission is to transform the traditional drug development process and bring important therapies to patients in need. Roivant Sciences Ltd is driven by a commitment to improve healthcare options and deliver value to their stakeholders.
Roivant Sciences Ltd is primarily active in the pharmaceutical and healthcare industries. With a focus on developing and commercializing innovative therapies, Roivant Sciences Ltd aims to improve patient care and address unmet medical needs. By leveraging their unique approach to drug discovery and development, the company strives to make a significant impact in various therapeutic areas. Through strategic partnerships and a robust pipeline of investigational drug candidates, Roivant Sciences Ltd continues to drive advancements in healthcare with its commitment to innovation and improving patient outcomes.
The main competitors of Roivant Sciences Ltd in the market are Actinium Pharmaceuticals, Inc., Aclaris Therapeutics, Inc., Akorn, Inc., and Alkermes plc.
Roivant Sciences Ltd is a well-established pharmaceutical company with a rich history and background. Founded in 2014, Roivant Sciences has quickly gained recognition for its innovative approach to developing and commercializing transformative drugs. Headquartered in Basel, Switzerland, the company focuses on harnessing advanced technologies and data-driven solutions to tackle unmet medical needs. With a strong emphasis on strategic partnerships and collaborations, Roivant Sciences has attracted global attention for its success in bringing novel therapies to market. As a leading player in the healthcare industry, Roivant Sciences continues to revolutionize the treatment landscape, earning a reputation for its commitment to improving patients' lives and addressing critical healthcare challenges.
Roivant Sciences Ltd has achieved significant milestones in its journey. With a focus on innovative healthcare solutions, the company has made noteworthy achievements. One of the notable milestones is the successful approval of its flagship product, [Company Name], by regulatory authorities. Additionally, Roivant Sciences Ltd has established key strategic partnerships with leading pharmaceutical companies, further enhancing its global presence and research capabilities. The company's commitment to advancing medical research and development is exemplified by its continuous efforts in pioneering groundbreaking therapies and treatments. As a result, Roivant Sciences Ltd has positioned itself as a trusted and trailblazing player in the healthcare industry.
Roivant Sciences Ltd primarily operates in various countries and regions globally. As a biopharmaceutical company, Roivant Sciences Ltd has a significant presence in the United States, where its headquarters are located. The company has also expanded its operations to other regions, including Europe, Asia, and Latin America. With a focus on developing and commercializing innovative therapies, Roivant Sciences Ltd continues to establish a strong international footprint, leveraging its expertise to address patients' unmet needs in different markets worldwide.
Roivant Sciences Ltd represents a commitment to innovation, collaboration, and patient-centricity. With a strong corporate philosophy focused on transforming the biopharmaceutical industry, Roivant Sciences aims to address unmet medical needs by developing and commercializing novel therapies. The company values scientific excellence and prioritizes the advancement of groundbreaking technologies and therapeutics. Roivant Sciences also strives for transparency, integrity, and respect in all its interactions, forming strategic partnerships with leading healthcare organizations and experts worldwide. Through its core values and corporate philosophy, Roivant Sciences is dedicated to improving healthcare outcomes and enhancing the overall well-being of patients.
Analysts currently set an average price target of 27.26 USD for the Roivant Sciences stock (median: 26.52 USD), implying -33.2 % versus the latest price. The consensus is based on 18 analyst ratings.
18 analysts currently rate the Roivant Sciences stock: 16 recommend buying, 2 holding and 0 selling.
Converted at the current exchange rate, the Roivant Sciences share trades at 35.29 EUR (40.94 USD).
The Roivant Sciences share (ROIV) is listed on 4 stock exchanges, including: NASDAQ (ROIV), Frankfurt (87S.F), München (87S.MU), Düsseldorf (87S.DU).
Roivant Sciences Ltd is a global biotech company headquartered in Basel, Switzerland. They focus on developing innovative therapies to address unmet medical needs of people worldwide. Roivant Sciences specializes in creating "Vants," separate operating subsidiaries that specialize in specific therapy areas. They identify specific clinical needs where there is no suitable therapy available and then establish a specific Vant dedicated to the development of therapies in that area. Some of Roivant Sciences' Vants include Axovant, which focuses on developing therapies for neurological diseases such as Alzheimer's and dementia. Enzyvant is dedicated to developing new treatments for rare, severe diseases, particularly for patients where treatment is no longer possible due to the absence of existing therapies. Myovant, another Vant of Roivant Sciences, focuses on developing therapies for women's health conditions such as endometriosis and infertility. Roivant Sciences drives the development of innovative therapies through partnerships and spin-offs of existing companies, and expands its therapeutic focus through strategic acquisitions. For example, in 2019, Roivant acquired Silicon Therapeutics, specializing in computer-assisted drug modeling. In addition to its Vants, Roivant Sciences also operates data prediction models through its Roivant Digital division and utilizes artificial intelligence and machine learning to discover new molecules and therapeutic approaches. These technologies complement the work of the company's Vants and enable faster and more efficient therapy development. Overall, Roivant Sciences has focused on developing therapies for diseases with high medical necessity. At the same time, the company strives to accelerate the development of new therapies by promoting collaboration between different disciplines such as biotechnology, software development, and data analysis. As the demand for novel therapeutic options remains high, Roivant Sciences is well positioned to achieve further groundbreaking developments in the industry in the coming years.
The revenue of Roivant Sciences is 8.26 M USD. This figure is based on current financial data and reflects the company's business performance.
The profit of Roivant Sciences is -299.77 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Roivant Sciences is currently -98.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Roivant Sciences stock.
The price-to-sales ratio (P/S) of Roivant Sciences is currently 3,572.47. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Roivant Sciences stock.
The Eulerpool Quality Score for Roivant Sciences is 2/10.
The ISIN of Roivant Sciences is BMG762791017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Roivant Sciences is A3C4MS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Roivant Sciences is ROIV. The ticker symbol is used to trade Roivant Sciences shares on the stock exchange.
Roivant Sciences paid dividends every year for the past 0 years.
Roivant Sciences is assigned to the 'Health' sector.
The dividends of Roivant Sciences are distributed in USD.
Roivant Sciences stock
Roivant Sciences Peer Group
Roivant Sciences Ticker
Roivant Sciences FIGI
All fundamentals and in-depth analysis of Roivant Sciences
Our stock analysis for Roivant Sciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Roivant Sciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.